



Date: 22<sup>nd</sup> September, 2025

**To,**  
Corporate Relations Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Company Code: ACCPL**

Dear Sir/ Madam,

**Subject: Media Release: Secures Malawi cGMP Approval, Paving the Way for Direct Exports and Revenue Growth**

With reference to the captioned subject, please find enclosed herewith Media Release regarding Secures Malawi cGMP Approval, Paving the Way for Direct Exports and Revenue Growth.

For more details please visit: [www.accretionpharma.com](http://www.accretionpharma.com)

You are requested to kindly take on your record.

Thanking You.

Yours truly,  
**For Accretion Pharmaceuticals Limited**

**Harshad Rathod**  
**Director and CFO**  
**DIN: 09108392**

## **Business Update Release**

### **Secures Malawi cGMP Approval, Paving the Way for Direct Exports and Revenue Growth**

**Ahmedabad, 19<sup>th</sup> September 2025:** Accretion Pharmaceuticals Limited (NSE Emerge: ACCPL), a leading manufacturer of high-quality pharmaceutical formulations and contract development and manufacturing organization (CDMO) services, is thrilled to announce that it has received Current Good Manufacturing Practice (cGMP) plant approval from The Pharmacy and Medicines Regulatory Authority (PMRA), Malawi for a period of two years. This milestone enables direct exports to the Malawian market, further strengthening the Company's global footprint and supporting its robust growth trajectory.

The cGMP approval validates Accretion Pharmaceuticals Limited' commitment to maintaining the highest standards of quality and compliance in its manufacturing processes at its state-of-the-art facility in Xcelon Industrial Park, Ahmedabad, Gujarat, India. This certification opens new revenue streams by facilitating direct market access to Malawi, a growing pharmaceutical market in Africa, and is expected to positively impact the company's revenue in FY26 and beyond.

#### **Management Comment:**

Commenting on this development, **Mr. Harshad Nanubhai Rathod, Chairman, Director and CFO, Accretion Pharmaceuticals Limited** said:

*"I am immensely proud to announce our cGMP plant approval from The Pharmacy and Medicines Regulatory Authority, Malawi a testament to our unwavering commitment to quality and global standards. This milestone not only opens direct export opportunities to Malawi but also strengthens our position as a trusted CDMO partner in the African market.*

*Africa has always been a key focus geography for us, and this approval strengthens our ability to deepen relationships in the region. We expect this development to contribute meaningfully to our export revenues, diversify our market presence, and reinforce our mission of being a reliable global partner in healthcare. Our teams continue to work tirelessly to maintain the highest standards of compliance, innovation, and customer trust, ensuring sustainable growth for our business and value creation for our investors.*

## Company Overview

Accretion Pharmaceuticals Limited, established in 2012 and headquartered in Ahmedabad, Gujarat, India, is a fast-growing pharmaceutical company listed on the NSE Emerge platform (since May 21, 2025). Specializing in the development, manufacturing, and marketing of high-quality generic and branded formulations, the Company offers a diverse portfolio including tablets, capsules, oral liquids, oral powder and external preparation. Operating from a state-of-the-art facility at Xcelon Industrial Park, Ahmedabad, Gujarat, India. Accretion provides contract development and manufacturing organization (CDMO) services, private labeling and third-party manufacturing for merchant exporters, domestic marketers and international clients.

Our Company is WHO- cGMP, GLP, Cambodia GMP, Rwanda GMP, Nigeria GMP, Malawi GMP, ISO 9001:2015, ISO 14001:2015 and ISO 22000:2018 certified and is led by an experienced board of directors, and a professional and experienced management team with extensive experience in the pharmaceutical.

**For more details please visit:** [www.accretionpharma.com](http://www.accretionpharma.com)

*For further information please contact:*

<i>Company:</i> <b>CS Roshni Shah</b> Company Secretary & Compliance Officer Accretion Pharmaceuticals Limited E-mail: <a href="mailto:compliance@accretionpharma.com">compliance@accretionpharma.com</a>	<i>Investor Relations:</i> <b>Savli Mangle / Rupesh Rege</b> Adfactors PR Pvt. Ltd. Email: <a href="mailto:savli.Mangle@adfactorspr.com">savli.Mangle@adfactorspr.com</a> <a href="mailto:rupesh.rege@adfactorspr.com">rupesh.rege@adfactorspr.com</a>
---	--

**Note:** Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.